Influence of blood and serum on the antistaphylococcal activity of lysostaphin. J. Bacteriol. 91:725-728. 1966 Although the in vitro effectiveness of lysostaphin against large numbers of coagulase-positive clinical strains of Staphylococcus aureus has been documented (2-4, 6), and its in vivo activity (5) and its mode of action (1) have been reported, a more extensive evaluation of its lytic activity in the presence of blood and serum was undertaken, prior to conducting more sophisticated staphylococcal infection models in animals. The data of Schindler and Schuhardt (4) suggested qualitatively that lysostaphin retains much of its lytic activity in the presence of human serum.
Although the in vitro effectiveness of lysostaphin against large numbers of coagulase-positive clinical strains of Staphylococcus aureus has been documented (2) (3) (4) 6) , and its in vivo activity (5) and its mode of action (1) have been reported, a more extensive evaluation of its lytic activity in the presence of blood and serum was undertaken, prior to conducting more sophisticated staphylococcal infection models in animals. The data of Schindler and Schuhardt (4) suggested qualitatively that lysostaphin retains much of its lytic activity in the presence of human serum.
In the work reported here, the effect of sera of human and animal origin on the antistaphylococcal activity of lysostaphin was studied by use of the criteria of cell lysis of S. aureus, viable-cell counts, and minimal inhibitory concentration end points as a function of time. The results show that serum exhibits a minimal antagonizing effect on the antibiotic activity of lysostaphin.
MATERIALS AND METHODS
Lysis ofS. aureus. The Copenhagen and FDA 209P strains of S. aureus were used. Lysis of viable-cell suspensions with graded concentrations of lysostaphin in the presence and absence of pooled human sera was measured as the percentage reduction in optical density (OD) at 620 mp after incubation for 10 or 20 min at 37 C. A Coleman Jr. spectrophotometer was used. Final assay volumes of 1.5 ml (in 10 by 75 mm culture tubes) or 6.0 ml (in 18 by 150 mm culture tubes), and initial OD readings of 0.250 to 0.275 were employed.
Tris(hydroxymethyl)aminomethane (Tris; Fisher, Primary Standard grade; 0.05 M in 0.145 M sodium chloride, pH 7.5) served as the buffer.
Viable-cell counts ofS. aureus. Viable-cell counts of the S. aureus cell suspensions in buffer or human sera were determined after exposure to lysostaphin by plating appropriate dilutions on plates of Staphylococcus Medium No. 110 (Difco) containing 0.1% trypsin (Difco). A 1.0% solution of trypsin was sterilized by Seitz filtration, and was added to sterile, cooled agar medium. Trypsin was employed to inactivate residual lysostaphin. Plate counts were made after 48 hr of incubation (24 hr at 37 C and 24 hr at 28 C). Solutions of lysostaphin in buffer were sterilized by Millipore filtration (0.45 ,u), by use of a stainless-steel grid as a support for the membrane filter.
Effect of serum on minimal inhibitory concentrations of lysostaphin. Minimal inhibitory concentrations were determined for a number of clinical isolates of S. aureus (bacteriophage 80/81 and UC18 types) by procedures previously described (6) . The heparinized bovine blood, obtained from freshly slaughtered animals, was centrifuged, and the plasma was sterilized by filtration (Millipore or Seitz), subdivided, and promptly frozen.
Addition of lysostaphin and recovery of its biological activity from serum and blood. Lysostaphin was added 725 ZYGMUNT, BROWDI to human serum to give a final concentration of 1 mg/ ml, and the solution was incubated at 37 C; portions were assayed for antibiotic activity after 0, 1, 2, and 3 hr.
A similar concentration of lysostaphin in 10 ml of heparinized whole rabbit blood was obtained, and was incubated at 37 C for 0, 1, and 2 hr; 2-ml portions of blood were centrifuged at 5 C at each sampling period, and the plasma was assayed for lysostaphin content. The red blood cells were suspended in 10 ml of 0.2 M calcium acetate (pH 7.1), agitated at 28 C in a 50-ml Erlenmeyer flask for 10 min, and centrifuged at 5 C; the supematant fluid was assayed for lysostaphin con- ing the assay. Under these circumstances, only about one-third of the antibiotic activity was detected in the 10-min assay.
Taken in toto, the data indicate that appreciable binding of lysostaphin to serum proteins does occur, that higher concentrations of the antibiotic may be necessary in vivo than would be estimated from in vitro data, but that the binding is not an irreversible one.
In the case of whole blood, it was found similarly that lysostaphin is not destroyed to any appreciable extent. The data in Table 3 suggest that the antibiotic does not bind appreciably to erythrocytes, nor enter red blood cells readily in whole rabbit blood.
To assess the contribution of anticoagulants to the biological activity of lysostaphin, a comparison was made of the antibiotic activity recoverable from buffer, from normal serum, and from heparin-, EDTA-, and citrate-treated blood and buffer. Dog blood was used in this experiment. No significant destruction of lysostaphin activity occurred within the 2-hr test period with any of the treatments used (Table 4) . Binding of lysostaphin to red blood cells or penetration of these cells is negligible, and confirms the findings obtained with rabbit blood.
By still another criterion, the growth-inhibitory activity of lysostaphin against 30 clinical isolates of S. aureus was not influenced greatly by the presence of 25 % bovine serum (Table 5) .
These studies on the effect of plasma, serum, and whole blood on the antistaphylococcal activity of lysostaphin reveal that, although the antibiotic may bind to blood proteins, the binding appears to be reversible. 
